Clinical Trial

Spironolactone Therapy in Chronic Stable Right HF Trial

Study Description

Spironolactone Therapy in Chronic Stable Right HF Trial

The purpose of this study is to evaluate the safety, tolerability and mechanistic effects of spironolactone, an aldosterone receptor antagonist, on sympathetic nervous system activity and right heart function and remodeling in patients with chronic right heart failure.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - Spironolactone

Spironolactone 12.5mg daily up to a maximum dose of 50 mg daily if tolerated for a total duration of 12 weeks.

Drug - Placebo

Placebo daily for a total of duration of 12 weeks

Radiation - PET/CT Scan: Two PET scans using 1. C-11 HED and 2. N-13 Ammonia or rubidium-82

At baseline and 12 weeks, all participants will undergo rest perfusion PET imaging according to standard protocols with either 82-Rb or N-13 NH3, followed by C-11 HED PET.

Diagnostic Test - Cardiac MRI (Gadolinium enhanced)

At baseline and 12 weeks all participants will undergo cMR to assess RV function and structure. We will acquire precontrast T2 and native T1 maps, and post gadolinium T1 maps.

Additional Information

Official Study Title

Spironolactone Therapy in Chronic Stable Right HF Trial

Clinical Trial ID

NCT03344159

ParticipAid ID

7axDna